Medtide (HKG:3880) completed the conversion of 68.2 million unlisted shares into Hong Kong-listed shares on Monday, according to a same-day Hong Kong bourse filing.
The listing of the peptide-focused CRDMO's converted shares on the Hong Kong stock exchange will begin at 9:00 am on March 10.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.